Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 Par Value
-
Shares outstanding
-
13.1M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
7.53M
-
Shares change
-
+800K
-
Total reported value, excl. options
-
$56M
-
Value change
-
+$4.83M
-
Number of buys
-
15
-
Number of sells
-
-8
-
Price
-
$7.43
Significant Holders of Avalo Therapeutics, Inc. - Common Stock, $0.001 Par Value (AVTX) as of Q4 2024
37 filings reported holding AVTX - Avalo Therapeutics, Inc. - Common Stock, $0.001 Par Value as of Q4 2024.
Avalo Therapeutics, Inc. - Common Stock, $0.001 Par Value (AVTX) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.53M shares
of 13.1M outstanding shares and own 57.56% of the company stock.
Largest 10 shareholders include BVF INC/IL (1.04M shares), Ikarian Capital, LLC (970K shares), RA CAPITAL MANAGEMENT, L.P. (967K shares), ORBIMED ADVISORS LLC (967K shares), Deep Track Capital, LP (867K shares), Affinity Asset Advisors, LLC (551K shares), COMMODORE CAPITAL LP (483K shares), TCG Crossover Management, LLC (483K shares), VANGUARD GROUP INC (166K shares), and BOOTHBAY FUND MANAGEMENT, LLC (164K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.